Silence Therapeutics plc — Director's Dealing 2018

Jul 17, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9003U

Silence Therapeutics PLC

17 July 2018

Grant of Restricted Stock Units

17 July 2018

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has today granted nominal cost restricted stock units ('RSUs') to David Horn Solomon, the Company's Chief Executive Officer, under the Silence Therapeutics plc 2018 Long Term Incentive Plan.  Details of the grant are summarised below.

Award of Restricted Stock Units:

Director	Position	RSUs Awarded	Total RSUs Held
David Horn Solomon	CEO	401,338	401,338

These nominal cost RSUs will vest in full on 16 July 2021.  The RSUs are subject to achievement of the performance condition that the Company's share price must be maintained above 157p for a period of 30 continuous days prior to vesting.   The RSUs are exercisable over the period of 7 years from the date of vesting. Claw-back and malus provisions apply.  There is a one-year holding period post exercise.  Each RSU entitles the holder to subscribe for an Ordinary Share at a subscription price of 5 pence per Ordinary Share equating to the nominal value.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	David Horn Solomon
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Silence Therapeutics plc
b)	LEI	213800SSURRJBX85SQ91
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each ISIN for Silence Therapeutics plc Ordinary Shares GB00B9GTXM62
b)	Nature of the transaction	Grant of restricted stock units under the Silence Therapeutics plc 2018 Long Term Incentive Plan
c)	Price(s) and volume(s)	Price(s)                                                  Volume(s) 5 pence per share (subscription price)      401,338
d)	Aggregated information -   Aggregated volume -   Price	N/A
e)	Date of the transaction	17 July 2018
f)	Place of the transaction	Outside a trading venue

Enquiries:

Silence Therapeutics plc Annalisa Jenkins, Executive Chair David Horn Solomon, Chief Executive Officer David Ellam, Chief Financial Officer	Tel: +44 (0) 20 3457 6900
Peel Hunt LLP (Nominated Adviser and Broker) James Steel/ Oliver Jackson	Tel: +44 (0) 20 7418 8900
Media & IR Enquiries Optimum Strategic Communications  Mary Clark/ Eva Haas/ Hollie Vile [email protected]	Tel: +44 (0) 20 3714 1788
IR Enquiries - US Burns McClellan John Grimaldi [email protected]	Tel: +1 (212) 213 0006

About Silence Therapeutics plc

Silence Therapeutics is developing a new modality of genetic medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome and be engineered to specifically silence the production of disease-associated proteins. Using enabling delivery systems, Silence has achieved an additional level of specificity by delivering therapeutic RNA molecules exclusively to target cells. Silence's proprietary technology platform provides an effective, safe and highly potent modular approach well suited to tackling life-threatening diseases. Silence aims on being a clinical stage company in 2019, while progressing a pipeline of earlier stage candidates against important gene targets directed at areas of high unmet medical need. In parallel, Silence continues to evolve its patent portfolio as new discoveries emerge from its innovative efforts to develop the next generation of RNAi medicines.

Silence has out-licensed technology to Quark Pharmaceuticals for use in Delayed Graft Function and Acute Kidney Injury. Both programmes are now in phase III. For more information, please visit: http://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHBGGDRUXBBGIR